T. Toptas, Kubra Bercem Kahraman, Zilan Topcu, H. Bostan, P. Kadıoğlu
{"title":"Thyroid diseases in patients with active endogenous Cushing’s syndrome","authors":"T. Toptas, Kubra Bercem Kahraman, Zilan Topcu, H. Bostan, P. Kadıoğlu","doi":"10.5472/marumj.1186788","DOIUrl":null,"url":null,"abstract":"Objective: Data about the impact of Cushing’s syndrome (CS) on thyroid is scarce. We aimed to identify the prevalence of thyroid \ndiseases in patients with CS. \nPatients and Methods: Nineteen patients with CS and 40 healthy participants were included in the study. All patients were tested \nfor free tri-iodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), anti-thyroglobulin (anti-Tg), and antithyroid \nperoxidase (anti-TPO) levels, and thyroid ultrasonography (US). \nResults: Overt hypothyroidism, subclinical hypothyroidism, and subclinical hyperthyroidism was evident in 5.3%, 5.3%, and 21.1% of \npatients with CS; and 2.5%, 7.5%, and 15% of healthy subjects, respectively. fT3 and fT4 levels were lower in patients with CS. None \nof the patients with CS and 27.5% of the control group had autoimmune thyroid disease (AITD), which was demonstrated by both \nUS findings and anti-TPO positivity (P=0.01). Frequency of thyroid nodule was 52.6% and 52.5% in patients with CS and controls, \nrespectively (P=0.99). \nConclusion: The prevalence of thyroid dysfunction, nodular thyroid disease, and goiter is comparable to healthy population. However, \nAITD is less prevalent among patients with CS. Although, hypercortisolism has an impact on hypothalamic-hypophyseal-thyroid \naxis, its clinical implication does not seem to be significant.","PeriodicalId":43341,"journal":{"name":"Marmara Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marmara Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5472/marumj.1186788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Data about the impact of Cushing’s syndrome (CS) on thyroid is scarce. We aimed to identify the prevalence of thyroid
diseases in patients with CS.
Patients and Methods: Nineteen patients with CS and 40 healthy participants were included in the study. All patients were tested
for free tri-iodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), anti-thyroglobulin (anti-Tg), and antithyroid
peroxidase (anti-TPO) levels, and thyroid ultrasonography (US).
Results: Overt hypothyroidism, subclinical hypothyroidism, and subclinical hyperthyroidism was evident in 5.3%, 5.3%, and 21.1% of
patients with CS; and 2.5%, 7.5%, and 15% of healthy subjects, respectively. fT3 and fT4 levels were lower in patients with CS. None
of the patients with CS and 27.5% of the control group had autoimmune thyroid disease (AITD), which was demonstrated by both
US findings and anti-TPO positivity (P=0.01). Frequency of thyroid nodule was 52.6% and 52.5% in patients with CS and controls,
respectively (P=0.99).
Conclusion: The prevalence of thyroid dysfunction, nodular thyroid disease, and goiter is comparable to healthy population. However,
AITD is less prevalent among patients with CS. Although, hypercortisolism has an impact on hypothalamic-hypophyseal-thyroid
axis, its clinical implication does not seem to be significant.
期刊介绍:
Marmara Medical Journal, Marmara Üniversitesi Tıp Fakültesi tarafından yılda üç kere yayımlanan multidisipliner bir dergidir. Bu dergide tıbbın tüm alanlarına ait orijinal araştırma makaleleri, olgu sunumları ve derlemeler İngilizce veya Türkçe olarak yer alır.